HC Wainwright Brokers Lower Earnings Estimates for EPRX

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Research analysts at HC Wainwright decreased their Q3 2025 EPS estimates for shares of Eupraxia Pharmaceuticals in a research note issued on Wednesday, August 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.20) for the quarter, down from their previous forecast of ($0.18). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.80) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($1.01) EPS, FY2028 earnings at ($1.04) EPS and FY2029 earnings at ($0.26) EPS.

Several other research analysts have also commented on the company. Cantor Fitzgerald began coverage on Eupraxia Pharmaceuticals in a report on Thursday, July 24th. They set an “overweight” rating and a $11.00 price objective for the company. Canaccord Genuity Group began coverage on Eupraxia Pharmaceuticals in a report on Monday, June 16th. They set a “speculative buy” rating for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $11.00.

Eupraxia Pharmaceuticals Trading Up 0.8%

NASDAQ EPRX opened at $5.32 on Friday. Eupraxia Pharmaceuticals has a 12-month low of $2.20 and a 12-month high of $6.20. The company has a market cap of $191.31 million, a P/E ratio of -6.26 and a beta of 1.50. The company has a fifty day simple moving average of $5.07 and a 200 day simple moving average of $4.13.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05).

Institutional Trading of Eupraxia Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC purchased a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth approximately $31,000. Quadrature Capital Ltd purchased a new stake in Eupraxia Pharmaceuticals in the second quarter worth approximately $61,000. Raymond James Financial Inc. purchased a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth approximately $37,000. Bank of America Corp DE boosted its stake in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after buying an additional 10,059 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock worth $108,000 after buying an additional 16,017 shares in the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.